·
4 Min Read

The pandemic’s not over, and the overdose epidemic is getting worse

COVID-19 is leaving a growing number of Americans isolated and desperate, exacerbating the opioid epidemic that killed nearly 72,000 in U.S. last year.

Behavioral Health
·
2 Min Read

AMA statement on Justice Department settlement with Purdue Pharma

Any settlement should be used exclusively for data collection, research, education, overdose prevention, stigma elimination, and evidence-based treatment.

Press Releases
·
2 Min Read

Aug. 28, 2020: State Advocacy Update

Select 2020 research relating to the nation’s drug overdose epidemic in the latest State Advocacy Update.

Advocacy Update
·
5 Min Read

Aug. 21, 2020: State Advocacy Update

State reports of increased opioid-related mortality continue to increase and more in the latest State Advocacy Update.

Advocacy Update
illustration of tiny pharmacist holding up prescription bottle among other prescription bottles
·
3 Min Read

The opioid epidemic: What is the physician’s responsibility?

With the growing opioid crisis, pain management and approaches to prescribing have taken on a new ethical component. Learn more from the AMA Journal of Ethics.

Ethics
Person looking out at a cityscape
·
4 Min Read

How patients’ trauma perpetuates the nation’s overdose epidemic

To end the drug overdose epidemic, experts say to take holistic view, focus on preventing overdoses in general and avoid fixating on a specific drug.

Behavioral Health
·
14 Min Read

Patrice Harris, MD, MA, discusses the nation's drug overdose epidemic

The AMA is leading the fight against the COVID-19 pandemic. See daily video updates on how the AMA is fighting COVID-19 by discussing the nation's drug overdose epidemic and COVID-19.

series
Behavioral Health
AMA Update
Figure sitting on park bench
·
5 Min Read

Nation’s drug overdose epidemic requires new policy focus

The nation’s overdose epidemic is being increasingly fueled by illicitly manufactured fentanyl, psychostimulants, heroin, cocaine and drug combinations.

Behavioral Health
·
2 Min Read

AMA applauds FDA for requiring naloxone information on opioid labels

The new labeling can serve as a starting point for discussion between patients and physicians about risks and benefits associated with opioids.

Press Releases